| Year |
Title |
Altmetric |
| 2022
|
Consensus Conference Statement on the General Use of Near-infrared Fluorescence Imaging and Indocyanine Green Guided Surgery: Results of a Modified Delphi Study.
Annals of Surgery.
275:685-691.
2022
|
|
| 2022
|
Hyperintensity of integrin-targeted fluorescence agent IntegriSense750 accurately predicts flap necrosis compared to Indocyanine green
2022
|
|
| 2021
|
Author Correction: Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model (Scientific Reports, (2021), 11, 1, (15384), 10.1038/s41598-021-94887-x).
Scientific Reports.
11.
2021
|
|
| 2021
|
Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model.
Scientific Reports.
11.
2021
|
|
| 2021
|
Predicting Schwannoma Growth in a Tumor Model Using Targeted Imaging
2021
|
|
| 2020
|
A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma.
Oncogene.
39:6961-6974.
2020
|
|
| 2020
|
Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study.
Journal of oral surgery, anesthesia, and hospital dental service.
78:1736-1747.
2020
|
|
| 2020
|
Comparison of panitumumab-IRDye800CW and 5-aminolevulinic acid to provide optical contrast in a model of glioblastoma multiforme.
Molecular Cancer Therapeutics.
19:1922-1929.
2020
|
|
| 2020
|
Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models.
European Journal of Nuclear Medicine and Molecular Imaging.
47:1412-1426.
2020
|
|
| 2020
|
Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
PLoS One.
15.
2020
|
|
| 2020
|
Surgical margins in oral cavity squamous cell carcinoma: Current practices and future directions
2020
|
|
| 2019
|
Fluorescence Imaging of Nerves during Surgery.
Annals of Surgery.
270:69-76.
2019
|
|
| 2019
|
Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer.
Journal of Surgical Research.
239:44-51.
2019
|
|
| 2019
|
Proceedings: Pathways for successful translation of new imaging agents and modalities—phase III studies.
Journal of Nuclear Medicine.
60:736-744.
2019
|
|
| 2019
|
Genetic strategy to decrease complement activation with adenoviral therapies.
PLoS One.
14.
2019
|
|
| 2019
|
Adjuvant anti-angiogenic therapy enhances chemotherapeutic uptake in a murine model of head and neck cancer *.
Journal of Drug Targeting.
27:193-200.
2019
|
|
| 2019
|
Current and future imaging methods for evaluating response to immunotherapy in neuro-oncology.
Theranostics.
9:5085-5104.
2019
|
|
| 2018
|
Determination of tumor margins with surgical specimen mapping using near-infrared fluorescence.
Cancer Research.
78:5144-5154.
2018
|
|
| 2018
|
Ultrasound-Triggered Delivery of Anticancer Therapeutics from MRI-Visible Multilayer Microcapsules.
Advanced Therapeutics.
1.
2018
|
|
| 2018
|
Evaluation of optical imaging agents in a fluorescence-guided surgical model of head and neck cancer.
Surgical Oncology.
27:225-230.
2018
|
|
| 2018
|
Evaluation of fluorescence-guided surgery agents in a murine model of soft tissue fibrosarcoma
2018
|
|
| 2018
|
Recommendations for reporting on emerging optical imaging agents to promote clinical approval.
Theranostics.
8:5336-5347.
2018
|
|
| 2018
|
Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers..
Theranostics.
8:2488-2495.
2018
|
|
| 2017
|
Characterizing the detection threshold for optical imaging in surgical oncology
2017
|
|
| 2017
|
Fluorescence Imaging for Cancer Screening and Surveillance.
Molecular Imaging and Biology.
19:645-655.
2017
|
|
| 2017
|
T 1-Enhanced MRI-visible nanoclusters for imaging-guided drug delivery.
Nanoscale.
9:11785-11792.
2017
|
|
| 2017
|
Sensitivity and specificity of cetuximab-IRDye800CW to identify regional metastatic disease in head and neck cancer.
Clinical Cancer Research.
23:4744-4752.
2017
|
|
| 2017
|
Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation.
Molecular Imaging and Biology.
19:610-616.
2017
|
|
| 2017
|
Laser-assisted indocyanine green dye angiography for postoperative fistulas after salvage laryngectomy.
JAMA Otolaryngology-Head and Neck Surgery.
143:775-781.
2017
|
|
| 2017
|
Beyond the margins: Real-time detection of cancer using targeted fluorophores.
Nature Reviews Clinical Oncology.
14:347-364.
2017
|
|
| 2017
|
Regulatory aspects of optical methods and exogenous targets for cancer detection.
Cancer Research.
77:2197-2206.
2017
|
|
| 2017
|
Characterizing the utility and limitations of repurposing an open-field optical imaging device for fluorescence-guided surgery in head and neck cancer patients.
Journal of Nuclear Medicine.
58:246-251.
2017
|
|
| 2017
|
Effects of Neoadjuvant Chemotherapy and Radiotherapy on Flap Perfusion in a Novel Mouse Model Using Standard Clinical Assessment and Near-Infrared Fluorescence Angiography.
Archives of Otolaryngology and Rhinology.
038-042.
2017
|
|
| 2017
|
Oncologic Procedures Amenable to Fluorescence-guided Surgery.
Annals of Surgery.
266:36-47.
2017
|
|
| 2017
|
Specimen mapping in head and neck cancer using fluorescence imaging.
Laryngoscope Investigative Otolaryngology.
2:447-452.
2017
|
|
| 2016
|
Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies
2016
|
|
| 2016
|
Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck cancer models.
Cancer Medicine.
5:1526-1534.
2016
|
|
| 2016
|
Biodistribution Study of Intravenously Injected Cetuximab-IRDye700DX in Cynomolgus Macaques.
Molecular Imaging and Biology.
18:232-242.
2016
|
|
| 2016
|
Fluorescence imaging to localize head and neck squamous cell carcinoma for enhanced pathological assessment
2016
|
|
| 2016
|
On the horizon: Optical imaging for cutaneous squamous cell carcinoma
2016
|
|
| 2016
|
SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic Cancer xenografts.
Molecular Cancer Therapeutics.
15:680-688.
2016
|
|
| 2016
|
Standardized model for predicting flap failure using indocyanine green dye.
Proceedings of SPIE.
9696.
2016
|
|
| 2016
|
Successful translation of fluorescence navigation during oncologic surgery: A consensus report.
Journal of Nuclear Medicine.
57:144-150.
2016
|
|
| 2015
|
Molecular Ultrasound Imaging of Tissue Inflammation Using an Animal Model of Acute Kidney Injury.
Molecular Imaging and Biology.
17:786-792.
2015
|
|
| 2015
|
Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW.
British Journal of Neurosurgery.
29:850-858.
2015
|
|
| 2015
|
Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer.
Clinical Cancer Research.
21:3658-3666.
2015
|
|
| 2015
|
A ratiometric threshold for determining presence of cancer during fluorescence-guided surgery
2015
|
|
| 2015
|
In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas.
Scientific Reports.
5.
2015
|
|
| 2015
|
IND-Directed Safety and Biodistribution Study of Intravenously Injected Cetuximab-IRDye800 in Cynomolgus Macaques.
Molecular Imaging and Biology.
17:49-57.
2015
|
|
| 2015
|
Breast Cancer Imaging Using the Near-Infrared Fluorescent Agent, CLR1502..
Molecular Imaging.
14:7290201400040.
2015
|
|
| 2015
|
Laparoscopic fluorescent visualization of the ureter with intravenous IRDye800CW.
Journal of Minimally Invasive Gynecology.
22:799-806.
2015
|
|
| 2015
|
The status of contemporary image-guided modalities in oncologic surgery.
Annals of Surgery.
261:46-55.
2015
|
|
| 2015
|
Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies.
Cancer Biology and Therapy.
16:790-798.
2015
|
|
| 2014
|
A standardized light-emitting diode device for photoimmunotherapy.
Journal of Nuclear Medicine.
55:1893-1898.
2014
|
|
| 2014
|
Volumetric contrast-enhanced ultrasound imaging of renal perfusion.
Journal of Ultrasound in Medicine.
33:1427-1437.
2014
|
|
| 2014
|
A dual-reporter, diagnostic vector for prostate cancer detection and tumor imaging
2014
|
|
| 2014
|
Antibody-based imaging strategies for cancer.
Cancer and Metastasis Reviews.
33:809-822.
2014
|
|
| 2014
|
Biodistribution of P-selectin targeted microbubbles.
Journal of Drug Targeting.
22:387-394.
2014
|
|
| 2014
|
Breast cancer imaging using the near-infrared fluorescent agent, CLR1502.
Molecular Imaging.
13.
2014
|
|
| 2014
|
Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer.
Ultrasound in Medicine and Biology.
40:755-764.
2014
|
|
| 2013
|
Alpha-CaMKII plays a critical role in determining the aggressive behavior of human osteosarcoma.
Molecular Cancer Research.
11:349-359.
2013
|
|
| 2013
|
Optical fluorescent imaging to monitor temporal effects of microbubble-mediated ultrasound therapy.
IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.
60:281-289.
2013
|
|
| 2013
|
An Animal Model Allowing Controlled Receptor Expression for Molecular Ultrasound Imaging.
Ultrasound in Medicine and Biology.
39:172-180.
2013
|
|
| 2013
|
Enhancement of Adenovirus Delivery after Ultrasound-Stimulated Therapy in a Cancer Model.
Ultrasound in Medicine and Biology.
39:2374-2381.
2013
|
|
| 2012
|
Systemic delivery of a breast cancer-detecting adenovirus using targeted microbubbles.
Cancer Gene Therapy.
19:545-552.
2012
|
|
| 2012
|
Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma.
JAMA Otolaryngology-Head and Neck Surgery.
138:662-668.
2012
|
|
| 2012
|
Microbubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer.
Journal of Drug Targeting.
20:43-54.
2012
|
|
| 2011
|
Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells.
Molecular Cancer Research.
9:1008-1017.
2011
|
|
| 2011
|
Model System Using Controlled Receptor Expression for Evaluating Targeted Ultrasound Contrast Agents.
Ultrasound in Medicine and Biology.
37:1306-1313.
2011
|
|
| 2011
|
A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature.
Journal of Ultrasound in Medicine.
30:921-931.
2011
|
|
| 2011
|
A genetic strategy for combined screening and localized imaging of breast cancer.
Molecular Imaging and Biology.
13:452-461.
2011
|
|
| 2010
|
Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks.
Journal of Ultrasound in Medicine.
29:577-585.
2010
|
|
| 2009
|
Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
Cancer Biology and Therapy.
8:1109-1116.
2009
|
|
| 2008
|
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenograftsby diffusion-weighted magnetic resonance imaging.
Cancer Research.
68:8369-8376.
2008
|
|
| 2008
|
Breast tumor xenografts: Diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody.
Radiology.
248:844-851.
2008
|
|
| 2008
|
Endotoxin-induced proteolytic reduction in hepatic growth hormone (GH) receptor: A novel mechanism for GH insensitivity
2008
|
|
